论文信息 - KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer - 字舞流文

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

V. Heinemann | S. Ormanns | J. Neumann | T. Kirchner | A. Jung | S. Boeck | D. Modest | M. Haas | R. Laubender | R. Egg | C. Goritschan